GIP derivatives and uses thereof

US10604555B2 · kind B2 · utility

Assignee

• Novo Nordisk A/S · DK

Inventors

• Wouter Frederik Johan Hogendorf · Copenhagen, DK
• Henning Thoegersen · Farum, DK
• Nicholas Raymond Cox · Seattle, US
• Patrick James Knerr · Plainfield, US
• Richard D. DiMarchi · Carmel, US
• Brian Finan · Bloomington, US
• Jesper Lau · Farum, DK
• Steffen Reedtz-Runge · Copenhagen, DK
• Fa Liu · Watchung, US

Key dates

• Filing date: May 3, 2019
• Grant date: Mar 31, 2020
• Expiry date: May 3, 2039

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61K38/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to novel peptides that are derivatives of glucose-dependent insulinotropic polypeptide (GIP) analogues having improved physical stability in solution and a protracted profile of action. More particularly the invention relates to such peptides that are agonists at the GIP receptor and to their use in weight management or for treatment of diseases such as obesity, diabetes or non-alcoholic steatohepatitis (NASH). The peptides comprise a lysine residue at a position corresponding to position 24 of hGIP(1-31), and comprise a negatively charged modifying group attached to the epsilon amino group of the lysine residue.